The University of Oxford and Astrazeneca suspend the clinical tests of the COVID-19 vaccine
400
In phase III of the clinical sessions, vaccination tests that are being carried out by the University of Oxford and Astrazeneca have been suspended, due to the serious health problems of one of the participants.
Eight other candidates in phase III, one of which has generated the greatest hope: Some European countries had already reached purchase agreements after marketing authorization.
However, to obtain the authorization it is essential to overcome phase III. In the first two phases, it is necessary to prove, in dozens of volunteers, that the vaccine is safe and effective. The next phase consists of fine-tuning efficiency, determining doses and ensuring that there are no side effects on thousands of volunteers (in this case 30,000). Now, until the problems of the volunteer and the vaccines are clarified, the research has been suspended.
Astrazeneca has indicated that this type of incidences are common in the development of drugs. On the other hand, some experts have highlighted that what happened shows that the procedure for the development of vaccines is transparent and reliable.
>> Extensive report on the covid-19 vaccine in the September magazine: Covid-19 vaccine: health sovereignty or social responsibility
Zu idazle
Zientzia aldizkaria
